HUE049154T2 - Készítmények a MASP-2-függõ komplement-aktiválás gátlására - Google Patents

Készítmények a MASP-2-függõ komplement-aktiválás gátlására

Info

Publication number
HUE049154T2
HUE049154T2 HUE12779347A HUE12779347A HUE049154T2 HU E049154 T2 HUE049154 T2 HU E049154T2 HU E12779347 A HUE12779347 A HU E12779347A HU E12779347 A HUE12779347 A HU E12779347A HU E049154 T2 HUE049154 T2 HU E049154T2
Authority
HU
Hungary
Prior art keywords
acitivation
compositions
dependent complement
inhibiting masp
masp
Prior art date
Application number
HUE12779347A
Other languages
English (en)
Inventor
Thomas Dudler
Wayne Gombotz
James Parent
Clark Tedford
Anita Kavlie
Urs Hagemann
Herald Reiersen
Sergej Kiprijanov
Original Assignee
Omeros Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47090380&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HUE049154(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp filed Critical Omeros Corp
Publication of HUE049154T2 publication Critical patent/HUE049154T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21104—Mannan-binding lectin-associated serine protease-2 (3.4.21.104)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
HUE12779347A 2011-05-04 2012-05-04 Készítmények a MASP-2-függõ komplement-aktiválás gátlására HUE049154T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161482567P 2011-05-04 2011-05-04

Publications (1)

Publication Number Publication Date
HUE049154T2 true HUE049154T2 (hu) 2020-09-28

Family

ID=47090380

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE12779347A HUE049154T2 (hu) 2011-05-04 2012-05-04 Készítmények a MASP-2-függõ komplement-aktiválás gátlására

Country Status (25)

Country Link
US (6) US9011860B2 (hu)
EP (2) EP3725811A3 (hu)
JP (5) JP5891298B2 (hu)
KR (3) KR101641057B1 (hu)
CN (2) CN107011443B (hu)
AU (1) AU2012250627B2 (hu)
BR (1) BR112013028429B1 (hu)
CA (3) CA2832871C (hu)
CL (1) CL2013003140A1 (hu)
CY (1) CY1123212T1 (hu)
DK (1) DK2704743T3 (hu)
ES (1) ES2795667T3 (hu)
HR (1) HRP20200887T1 (hu)
HU (1) HUE049154T2 (hu)
IL (4) IL229208B (hu)
LT (1) LT2704743T (hu)
ME (1) ME03755B (hu)
MX (3) MX347691B (hu)
PL (1) PL2704743T3 (hu)
PT (1) PT2704743T (hu)
RS (1) RS60541B1 (hu)
RU (3) RU2636038C2 (hu)
SI (1) SI2704743T1 (hu)
WO (1) WO2012151481A1 (hu)
ZA (1) ZA201308943B (hu)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101874042B9 (zh) 2007-09-26 2019-01-01 中外制药株式会社 利用cdr的氨基酸取代来改变抗体等电点的方法
LT2708559T (lt) 2008-04-11 2018-06-11 Chugai Seiyaku Kabushiki Kaisha Antigeną surišanti molekulė, galinti pakartotinai prisijungti prie dviejų ar daugiau antigeno molekulių
EP2647706B1 (en) 2010-11-30 2023-05-17 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
US9644035B2 (en) 2011-04-08 2017-05-09 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN103781492A (zh) 2011-04-08 2014-05-07 莱斯特大学 用于治疗与masp-2依赖性补体活化相关的状况的方法
CN107011443B (zh) * 2011-05-04 2021-04-30 奥默罗斯公司 用于抑制masp-2依赖的补体活化的组合物
US11236168B2 (en) 2012-08-24 2022-02-01 Chugai Seiyaku Kabushiki Kaisha Mouse FcγammaRII-specific Fc antibody
CN104870475B (zh) 2012-10-25 2019-11-08 美国比奥维拉迪维股份有限公司 抗补体C1s抗体和其用途
CA2889197A1 (en) 2012-11-02 2014-05-08 True North Therapeutics, Inc. Anti-complement c1s antibodies and uses thereof
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
JP2016514456A (ja) * 2013-03-15 2016-05-23 オメロス コーポレーション 生物活性ペプチド担持抗体を生成する方法およびそれを含む組成物
AU2014250434B2 (en) 2013-04-02 2019-08-08 Chugai Seiyaku Kabushiki Kaisha Fc region variant
ES2829913T3 (es) 2013-10-17 2021-06-02 Omeros Corp Procedimientos de tratamiento de afecciones asociadas con la activación del complemento dependiente de MASP-2
SG11201700841QA (en) 2014-12-19 2017-03-30 Chugai Pharmaceutical Co Ltd Anti-myostatin antibodies, polypeptides containing variant fc regions, and methods of use
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
PT3280440T (pt) 2015-04-06 2023-02-14 Bioverativ Usa Inc Anticorpos anti-c1s humanizados e métodos de utilização destes
CN106699888B (zh) 2015-07-28 2020-11-06 上海昀怡健康科技发展有限公司 一种pd-1抗体及其制备方法和应用
UA124094C2 (uk) 2015-11-09 2021-07-21 Омерос Корпорейшн Спосіб лікування стану, пов'язаного з masp-2-залежною активацією комплементу
US11359009B2 (en) 2015-12-25 2022-06-14 Chugai Seiyaku Kabushiki Kaisha Anti-myostatin antibodies and methods of use
EP3400012A4 (en) 2016-01-05 2019-12-11 University Of Leicester PROCESS FOR INHIBITING FIBROSIS IN A NEEDED SUBJECT
CN115137816A (zh) 2016-03-31 2022-10-04 奥默罗斯公司 抑制有需要的受试者的血管发生的方法
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
MX2019001448A (es) 2016-08-05 2019-09-13 Chugai Pharmaceutical Co Ltd Composicion para profilaxis o tratamiento de enfermedades relacionadas con interleucina 8 (il-8).
JOP20170170B1 (ar) * 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
SG10201607778XA (en) 2016-09-16 2018-04-27 Chugai Pharmaceutical Co Ltd Anti-Dengue Virus Antibodies, Polypeptides Containing Variant Fc Regions, And Methods Of Use
JOP20190068A1 (ar) * 2016-10-13 2019-04-01 Omeros Corp طرق لتقليل البول البروتيني في خاضع بشري يعاني من الاعتلال الكلوي a الناتج عن الجلوبيولين المناعي
TWI818919B (zh) * 2017-08-15 2023-10-21 美商歐米諾斯公司 用於治療和／ 或預防與造血幹細胞移植有關的移植物抗宿主病和／ 或瀰漫性肺泡出血和／ 或靜脈閉塞性病的方法
MX2020002077A (es) * 2017-08-25 2020-03-24 Omeros Corp Formulaciones de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentradas, kits y metodos para el tratamiento de sujetos que padecen sindrome hemolitico atipico.
MX2020009296A (es) 2018-03-15 2020-11-13 Chugai Pharmaceutical Co Ltd Anticuerpos anti-virus del dengue que tienen reactividad cruzada con el virus zika y metodos de uso.
US11584714B2 (en) 2018-05-29 2023-02-21 Omeros Corporation MASP-2 inhibitors and methods of use
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
US11161900B2 (en) * 2018-12-13 2021-11-02 Argenx Bvba Antibodies that specifically bind to human complement factor C2b
US12030853B2 (en) 2019-12-04 2024-07-09 Omeros Corporation MASP-2 inhibitors and methods of use
CA3159167A1 (en) 2019-12-04 2021-06-10 Neil S. Cutshall Masp-2 inhibitors and methods of use
JP2023504543A (ja) 2019-12-04 2023-02-03 オメロス コーポレーション Ｍａｓｐ－２阻害剤および使用方法
WO2021113686A1 (en) 2019-12-04 2021-06-10 Omeros Corporation Masp-2 inhibitors and methods of use
TW202319069A (zh) * 2020-03-06 2023-05-16 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
CN114634575A (zh) * 2020-12-16 2022-06-17 康诺亚生物医药科技（成都）有限公司 一种补体抑制剂的开发和应用
EP4288098A1 (en) * 2021-02-05 2023-12-13 Omeros Corporation Biomarker for assessing the risk of developing acute covid-19 and post-acute covid-19
CN115215937B (zh) * 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CN116981477A (zh) 2021-04-25 2023-10-31 江苏恒瑞医药股份有限公司 抗masp2抗体、其抗原结合片段及医药用途
CN116615544A (zh) * 2021-12-10 2023-08-18 舒泰神（北京）生物制药股份有限公司 特异性识别masp2的抗体及其应用
IL313331A (en) 2021-12-10 2024-08-01 Omeros Corp Therapeutic antibodies that bind to the SERINE PROTEASE domain of MASP-2 and uses thereof
CN116284412A (zh) * 2021-12-21 2023-06-23 沈阳三生制药有限责任公司 一种抗masp-2抗体及其制备方法与用途
WO2023174039A1 (en) * 2022-03-18 2023-09-21 Inmagene Biopharmaceuticals (Hangzhou) Co., Ltd. Masp-2-targetting antibodies and uses thereof
US20240228499A1 (en) 2022-11-30 2024-07-11 Omeros Corporation Masp-2 inhibitors and methods of use

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
JPH07238100A (ja) 1994-02-25 1995-09-12 Sumitomo Electric Ind Ltd ヒトのｍａｓｐに対するモノクローナル抗体
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
JPH10510540A (ja) 1994-12-12 1998-10-13 オメロス メディカル システムズ，インコーポレーテッド 灌注用溶液並びに疼痛、炎症及びけいれんの抑制法
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
US7083786B2 (en) 1997-04-03 2006-08-01 Jensenius Jens Chr MASP-2, a complement-fixing enzyme, and uses for it
JP2002532079A (ja) 1998-12-15 2002-10-02 ザ ブライハム アンド ウイミンズ ホスピタル， インコーポレイテッド 補体活性化に関連するレクチン補体経路を調節するための方法および産物
EP1200127B1 (en) 1999-07-21 2008-06-25 Omeros Corporation Solutions and methods for inhibition of pain, inflammation and cartilage degradation
US20010051754A1 (en) 1999-08-03 2001-12-13 Daria N. Lissy Plural stage toluene disproportionation process minimizing ethylbenzene
AU2001240020B9 (en) * 2000-03-01 2008-12-04 Medimmune, Llc High potency recombinant antibodies and method for producing them
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
DK1303591T3 (da) * 2000-07-13 2009-11-02 Helion Biotech Aps MASP-2, et komplementfikserende enzym, og anvendelser af det
EP1300419B1 (en) 2001-10-05 2007-06-13 Affimed Therapeutics AG Antibody of human origin for inhibiting thrombocyte aggregation
EP3269235B1 (en) * 2001-11-30 2022-01-26 Amgen Fremont Inc. Transgenic mice bearing human ig lambda light chain genes
EP1496835A4 (en) 2002-02-01 2006-10-18 Omeros Corp COMPOSITIONS AND METHODS FOR THE SYSTEMIC SUPPRESSION OF CARTON DECOMPOSITION
ES2601143T3 (es) 2002-07-19 2017-02-14 Omeros Corporation Copolímeros tribloque biodegradables, métodos de síntesis de los mismos, e hidrogeles y biomateriales preparados a partir de los mismos
WO2004076658A1 (ja) 2003-02-28 2004-09-10 Mitsubishi Pharma Corporation モノクローナル抗体およびそれをコードする遺伝子、ハイブリドーマ、医薬組成物ならびに診断試薬
ES2629344T3 (es) * 2003-05-12 2017-08-08 Helion Biotech Aps Anticuerpos contra la MASP-2
US7919094B2 (en) 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US20060018896A1 (en) * 2004-06-10 2006-01-26 University Of Leicester Methods for treating conditions associated with lectin-dependent complement activation
CA3102252A1 (en) * 2004-06-10 2005-12-29 Omeros Corporation Methods for treating conditions associated with masp-2 dependent complement activation
US8840893B2 (en) 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
GB0412966D0 (en) 2004-06-10 2004-07-14 Univ Leicester Genetically modified non-human mammals and cells
CA2735900A1 (en) 2008-09-19 2010-03-25 Medimmune, Llc Antibodies directed to dll4 and uses thereof
EP2356270B1 (en) * 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
BR112012008970A2 (pt) * 2009-10-16 2019-12-10 Omeros Corp uso de uma composição, e, composição
CN107011443B (zh) * 2011-05-04 2021-04-30 奥默罗斯公司 用于抑制masp-2依赖的补体活化的组合物
RU2018114903A (ru) * 2012-04-06 2019-03-04 Омерос Корпорейшн Композиции и способы ингибирования masp-1, и/или masp-2, и/или masp-3 для лечения пароксизмальной ночной гемоглобинурии

Also Published As

Publication number Publication date
IL266756A (en) 2019-07-31
JP2015227380A (ja) 2015-12-17
CN107011443A (zh) 2017-08-04
PT2704743T (pt) 2020-06-17
CN103687620A (zh) 2014-03-26
US10683367B2 (en) 2020-06-16
US20120282263A1 (en) 2012-11-08
ES2795667T3 (es) 2020-11-24
US20160002349A1 (en) 2016-01-07
CL2013003140A1 (es) 2014-05-23
HRP20200887T1 (hr) 2020-09-04
KR20160087917A (ko) 2016-07-22
RU2017137872A (ru) 2019-04-30
US20210054099A1 (en) 2021-02-25
CN103687620B (zh) 2017-10-13
KR20180086298A (ko) 2018-07-30
CA2832871A1 (en) 2012-11-08
CA3131223A1 (en) 2012-11-08
NZ715226A (en) 2017-07-28
DK2704743T3 (en) 2020-05-25
JP2014515922A (ja) 2014-07-07
RU2017137872A3 (hu) 2019-04-30
US20170088632A1 (en) 2017-03-30
RS60541B1 (sr) 2020-08-31
JP5891298B2 (ja) 2016-03-22
EP2704743A1 (en) 2014-03-12
MX347691B (es) 2017-05-09
CA2832871C (en) 2019-01-15
IL229208B (en) 2021-03-25
US9475885B2 (en) 2016-10-25
ZA201308943B (en) 2015-05-27
JP6352226B2 (ja) 2018-07-04
BR112013028429B1 (pt) 2022-11-08
CA3131223C (en) 2024-01-30
JP2020097630A (ja) 2020-06-25
KR20140006096A (ko) 2014-01-15
US20190119402A1 (en) 2019-04-25
CA3025762C (en) 2021-11-09
BR112013028429A2 (pt) 2020-07-21
MX2013012862A (es) 2013-12-02
US9011860B2 (en) 2015-04-21
RU2725958C2 (ru) 2020-07-07
EP3725811A3 (en) 2021-01-27
LT2704743T (lt) 2020-09-10
ME03755B (me) 2021-04-20
EP2704743A4 (en) 2014-11-05
CA3025762A1 (en) 2012-11-08
IL229208A0 (en) 2014-01-30
RU2636038C2 (ru) 2017-11-17
SI2704743T1 (sl) 2020-08-31
MX361175B (es) 2018-11-29
IL285522A (en) 2021-09-30
US11613589B2 (en) 2023-03-28
EP2704743B1 (en) 2020-03-11
RU2013153527A (ru) 2015-06-10
KR101641057B1 (ko) 2016-07-20
KR102024016B1 (ko) 2019-11-04
JP2018123148A (ja) 2018-08-09
WO2012151481A1 (en) 2012-11-08
US20240092938A1 (en) 2024-03-21
KR101882830B1 (ko) 2018-07-31
IL266756B (en) 2021-08-31
NZ733310A (en) 2021-12-24
MX2018014714A (es) 2021-11-16
EP3725811A2 (en) 2020-10-21
JP2022172275A (ja) 2022-11-15
JP6669800B2 (ja) 2020-03-18
AU2012250627B2 (en) 2016-01-07
AU2012250627A1 (en) 2013-03-21
US10047165B2 (en) 2018-08-14
NZ617487A (en) 2016-03-31
RU2020120539A (ru) 2021-12-23
CY1123212T1 (el) 2021-10-29
CN107011443B (zh) 2021-04-30
PL2704743T3 (pl) 2020-08-24

Similar Documents

Publication Publication Date Title
DK2704743T3 (en) Compositions for inhibiting masp-2 dependent complement acitivation
HK1203403A1 (en) Peracid-generating compositions
HK1192578A1 (zh) 抗結皮組合物
GB201117619D0 (en) Compositions
SG11201401335QA (en) Compositions
GB201117621D0 (en) Compositions
EP2763756A4 (en) BROMOFLUOROCARBON COMPOSITIONS
GB2496447B (en) Compositions
GB201110833D0 (en) Compositions
GB201103942D0 (en) Compositions
HK1201687A1 (en) Improved compositions
GB201110132D0 (en) compositions
GB201104849D0 (en) Compositions
GB201122214D0 (en) Compositions
GB201122216D0 (en) Compositions
GB201122213D0 (en) Compositions
GB201121028D0 (en) Compositions
GB201120406D0 (en) Compositions
GB201117234D0 (en) Compositions
GB201117165D0 (en) Compositions
GB201114629D0 (en) Compositions
GB201109121D0 (en) Compositions
GB201108338D0 (en) Compositions
GB201108040D0 (en) Compositions
GB201107998D0 (en) Compositions